Cargando…

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

PURPOSE: To compare treatment outcomes in patients with major depressive disorder treated with duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline for up to 6 months. PATIENTS AND METHODS: Data were taken from a 6-month prospective, observational study that included 1,549 major depressiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jia, Wang, Yun, Chen, Jun, Zhang, Yanlei, Yuan, Zheng, Yue, Li, Haro, Josep Maria, Moneta, Maria Victoria, Novick, Diego, Fang, Yiru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165742/ https://www.ncbi.nlm.nih.gov/pubmed/30310285 http://dx.doi.org/10.2147/NDT.S159800

Ejemplares similares

A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
por: Sanchez, Connie, et al.
Publicado: (2014)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick, Diego, et al.
Publicado: (2016)

Impact of Sertraline, Fluoxetine, and Escitalopram on Psychological Distress among United States Adult Outpatients with a Major Depressive Disorder
por: Adjei, Kwame, et al.
Publicado: (2023)

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting
por: Hong, Jihyung, et al.
Publicado: (2015)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

Antidepressant medication treatment patterns in Asian patients with major depressive disorder
por: Novick, Diego, et al.
Publicado: (2015)

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study
por: Novick, Diego, et al.
Publicado: (2017)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?
por: Novick, Diego, et al.
Publicado: (2013)

Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East
por: Hong, Jihyung, et al.
Publicado: (2017)

Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression
por: Chavda, Nilesh, et al.
Publicado: (2011)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation
por: Silva, Soraia, et al.
Publicado: (2021)

Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression
por: Lalit, Vaya, et al.
Publicado: (2004)

Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine
por: Luong, Thu-Lan T., et al.
Publicado: (2022)

Possible cross-sensitivity between sertraline and paroxetine in a panic disorder patient
por: Khairkar, Praveen H., et al.
Publicado: (2010)

Spectrophotometric Determination of the Antidepressants Sertraline and Paroxetine HCl using 2,4-Dinitrofluorobenzene
por: Walash, M. I., et al.
Publicado: (2010)

Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing
por: Weeks, Janis C., et al.
Publicado: (2018)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Long and Short Duration Exposures to the Selective Serotonin Reuptake Inhibitors (SSRIs) Fluoxetine, Paroxetine and Sertraline at Environmentally Relevant Concentrations Lead to Adverse Effects on Zebrafish Behaviour and Reproduction
por: Venkatachalam, Ananda Baskaran, et al.
Publicado: (2023)

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial
por: WANG, Zhiyang, et al.
Publicado: (2015)

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline
por: Feduccia, Allison A., et al.
Publicado: (2019)

Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007)

Sex differences in the course of schizophrenia across diverse regions of the world
por: Novick, Diego, et al.
Publicado: (2016)

Sertraline versus escitalopram in South Asians with moderate to severe major depressive disorder: (SOUTH-DEP) a double-blind, parallel, randomized controlled trial
por: Raza, Sidra, et al.
Publicado: (2023)

Antidepressants, sertraline and paroxetine, increase calcium influx and induce mitochondrial damage-mediated apoptosis of astrocytes
por: Then, Chee-Kin, et al.
Publicado: (2017)

Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine
por: Liang, Zihong, et al.
Publicado: (2021)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Effects of Sertraline and Fluoxetine on P-Glycoprotein at Barrier Sites: In Vivo and In Vitro Approaches
por: Kapoor, Amita, et al.
Publicado: (2013)

Predictors of duloxetine adherence and persistence in patients with fibromyalgia
por: Cui, Zhanglin, et al.
Publicado: (2012)

Effects of escitalopram and paroxetine on mTORC1 signaling in the rat hippocampus under chronic restraint stress
por: Seo, Mi Kyoung, et al.
Publicado: (2017)

Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons
por: Eckert, Laurent, et al.
Publicado: (2006)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study
por: Novick, Diego, et al.
Publicado: (2015)

Itch and skin rash from chocolate during fluoxetine and sertraline treatment: Case report
por: Cederberg, Jonas, et al.
Publicado: (2004)

Effect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline
por: Gjestad, Caroline, et al.
Publicado: (2015)

Discontinuation and dose adjustment of metoprolol after metoprolol‐paroxetine/fluoxetine co‐prescription in Dutch elderly
por: Bahar, Muh. Akbar, et al.
Publicado: (2018)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Cytotoxicity and reversal effect of sertraline, fluoxetine, and citalopram on MRP1- and MRP7-mediated MDR
por: Bin Kanner, Yuval, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1bk5bn01pcvg6ulsk3ncu94k68